Dimensional Fund Advisors LP Sells 18,315 Shares of Relx Plc $RELX

Key Points

• Dimensional Fund Advisors LP has reduced its stake in Relx Plc by 0.6%, selling 18,315 shares to retain approximately 3.17 million shares, valued at $159.88 million.
• Several other institutional investors have increased their positions in Relx, with Massachusetts Financial Services Co. MA boosting its stake by 103.7%.
• Following a recent upgrade from a "hold" to a "buy" rating, Relx currently has a consensus rating of "Buy" among analysts.

Dimensional Fund Advisors LP lessened its holdings in shares of Relx Plc (NYSE:RELX - Free Report) by 0.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,171,571 shares of the technology company's stock after selling 18,315 shares during the period. Dimensional Fund Advisors LP owned 0.17% of Relx worth $159,879,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RELX. Bleakley Financial Group LLC increased its stake in Relx by 1.5% in the 1st quarter. Bleakley Financial Group LLC now owns 14,147 shares of the technology company's stock worth $713,000 after purchasing an additional 207 shares in the last quarter. Cynosure Group LLC increased its position in shares of Relx by 3.5% in the first quarter. Cynosure Group LLC now owns 6,951 shares of the technology company's stock worth $350,000 after acquiring an additional 236 shares in the last quarter. Bridgewater Advisors Inc. lifted its position in shares of Relx by 2.1% in the 1st quarter. Bridgewater Advisors Inc. now owns 11,463 shares of the technology company's stock valued at $617,000 after acquiring an additional 238 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its stake in Relx by 3.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 8,159 shares of the technology company's stock worth $371,000 after purchasing an additional 267 shares during the period. Finally, Ascent Group LLC grew its position in Relx by 2.0% during the 4th quarter. Ascent Group LLC now owns 14,024 shares of the technology company's stock worth $637,000 after purchasing an additional 277 shares in the last quarter. 15.02% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Relx from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to MarketBeat.com, Relx currently has an average rating of "Buy".

Relx Stock Down 0.7%

RELX traded down $0.3350 during midday trading on Monday, hitting $48.1050. 172,019 shares of the company's stock traded hands, compared to its average volume of 868,233. The company has a debt-to-equity ratio of 2.55, a current ratio of 0.47 and a quick ratio of 0.42. The company has a market cap of $88.25 billion, a PE ratio of 25.86, a price-to-earnings-growth ratio of 3.16 and a beta of 0.88. The stock's fifty day simple moving average is $51.69 and its 200-day simple moving average is $51.50. Relx Plc has a one year low of $44.19 and a one year high of $56.33.

Relx Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, September 16th. Investors of record on Friday, August 8th will be paid a $0.2634 dividend. The ex-dividend date is Friday, August 8th. This represents a yield of 170.0%. Relx's dividend payout ratio (DPR) is presently 27.96%.

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.